COMPARISON OF EFFECTS OF ACE-INHIBITION WITH CALCIUM-CHANNEL BLOCKADE ON RENAL-DISEASE IN A MODEL COMBINING GENETIC-HYPERTENSION AND DIABETES

被引：28

作者：

RUMBLE, JR ^{[1
]}

DOYLE, AE ^{[1
]}

COOPER, ME ^{[1
]}

机构：

[1] UNIV MELBOURNE,HEIDELBERG REPATRIAT HOSP,DEPT MED,HEIDELBERG,VIC 3081,AUSTRALIA

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1995年 / 8卷 / 01期

关键词：

HYPERTENSION; DIABETES; ALBUMINURIA; PERINDOPRIL; LACIDIPINE;

D O I：

10.1016/0895-7061(94)00165-8

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

The aim of this study was to compare the renal effects of angiotensin converting enzyme (ACE) inhibition with calcium channel blockade in a model combining genetic hypertension with diabetes. Streptozotocin diabetes was induced in spontaneously hypertensive rats (SHR). The animals were then randomized to receive no treatment, the ACE inhibitor, perindopril, or the dihydropyridine calcium antagonist lacidipine. Body weight, systolic blood pressure, glycemic control, renal function, and albumin excretion rate (AER) were assessed serially over the 32-week study period. At week 32 the animals; were killed and glomerular volume was measured. Both antihypertensive regimens significantly reduced systolic blood pressure in diabetic SHR. There was no significant difference in glycemic control, serum creatinine, or glomerular filtration rate among the three groups at week 32. The ACE inhibitor perindopril significantly reduced AER and glomerular hypertrophy over the 32 weeks, whereas the calcium antagonist lacidipine failed to reduce AER or glomerular hypertrophy. Thus, in contrast to the effects of ACE inhibition, calcium channel blockade with lacidipine, despite significantly reducing blood pressure, failed to reduce renal injury in this model. These results support the hypothesis that antihypertensive regimens may differ in their capacity to protect the diabetic kidney, despite similar effects on systemic blood pressure.

引用

页码：53 / 57

页数：5

共 33 条

[1]

Mauer, Steffes, Azar, Et al., The effects of Goldblatt hypertension on development of the glomerular lesions of diabetes mellitus in the rat, Diabetes, 27, pp. 738-744, (1978)

[2]

Cooper, Allen, O'Brien, Et al., Effects of genetic hypertension on diabetic nephropathy in the rat-functional and structural characteristics, J Hypertens, 6, pp. 1009-1016, (1988)

[3]

Mogensen, Renal function changes in diabetes, Diabetes, 25, pp. 872-879, (1976)

[4]

Parving, Andersen, Smidt, Et al., Diabetic nephropathy and arterial hypertension, Diabetologia, 24, pp. 10-12, (1983)

[5]

Parving, Andersen, Smidt, Svendsen, Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy, Lancet, 1, pp. 1175-1178, (1983)

[6]

Mogensen, Long-term antihypertensive treatment inhibits progression of diabetic nephropathy, Br Med J, 285, pp. 685-688, (1982)

[7]

Cooper, Allen, O'Brien, Et al., Nephropathy in a model combining genetic hypertension with experimental diabetes: enalapril versus hydralazine and metoprolol therapy, Diabetes, 39, pp. 1575-1579, (1990)

[8]

Cooper, Rumble, Allen, Et al., Antihypertensive therapy in a model combining spontaneous hypertension with diabetes, Kidney Int, 41, pp. 898-903, (1992)

[9]

Cooper, Rumble, Gin, Lim-Joon, Diabetic renal microvascular disease: the role of hypertension and ACE inhibitors, Clin Exp Pharmacol Physiol, 19, pp. 23-27, (1992)

[10]

Micheli, Collodel, Semeraro, Et al., Lacidipine: a calcium antagonist with potent and long-lasting anti-hypertensive effects in animal studies, J Cardiovasc Pharmacol, 15, pp. 666-675, (1990)

← 1 2 3 4 →